Abstract:Objective: This study aimed to investigate the clinical implications of fasting serum insulin (FINS) levels in subjects with type 2 diabetes who were receiving insulin therapy. Methods: A total of 1,553 subjects with type 2 diabetes [774 subjects who had never received insulin treatment (N-INS) and 779 subjects who were receiving insulin therapy (constant insulin treatment, C-INS)] admitted to the Department of Endocrinology and Metabolism of Peking University People's Hospital were enrolled in this study. Their FINS levels were measured and those with hyperinsulinemia were identified. The underlying mechanisms of hyperinsulinemia were revealed by measuring insulin antibodies (IAs) and analyzing changes in FINS levels before and after polyethylene glycol (PEG) precipitation. In addition, the clinical characteristics of patients with different types of hyperinsulinemia were compared. Results: Higher FINS levels and a higher incidence (43.8%, 341/779) of hyperinsulinemia (FINS > 15 mu IU/mL) were observed in subjects with C-INS than in subjects with N-INS. Among subjects with C-INS and hyperinsulinemia, 66.9% (228/341) were IAs positive, and the incidence of IAs was found to be positively associated with FINS level. By performing PEG precipitation, we found that all subjects without IAs (i.e., those with real hyperinsulinemia) and 31.1% of subjects (71/228) with IAs (i.e., those with both real and IAs-related hyperinsulinemia) still had hyperinsulinemia after PEG precipitation, whereas FINS levels in the other 68.9% of subjects (157/228) with IAs were normal (IAs-related hyperinsulinemia) after PEG precipitation. Comparisons between the groups showed that subjects with real hyperinsulinemia showed more obvious insulin resistance characteristics, including higher lipid levels, BMIs, and homoeostasis model assessment2-estimated insulin resistance (HOMA2-IR) index, and were more likely to have hypertension, obesity, and metabolic syndromes (p < 0.05). However, the risk of hypoglycemia and glucose variability increased significantly in subjects with IAs compared with those without IAs. A cutoff of FINS to serum C-peptide ratio (>= 9.3 mu IU/ng) could be used to screen IAs in clinical practice with 83.3% sensitivity and 70% specificity. Conclusions: It is necessary to measure FINS in subjects with C-INS to distinguish between types of hyperinsulinemia, which should help to tailor treatment regimens.

Implication of Proinsulin to Insulin Ratio in the Basic and Clinical Research of Diabetes

Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes

[Proportion of Proinsulin Two Minutes after Arginine Stimulation: a Pilot Study].

The Secretion and Release of Serum Proinsulin in IVGTT

Proinsulin is an Independent Predictor of the Angiographical Characteristics of Coronary Atherosclerosis

Clinical Implication of Islet Cell Regeneration Studies

Study on the proinsulin secretion after arginine stimulation test and its relationship with plasma glucose level in type 2 diabetes

IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance

The Clinical Implications of Fasting Serum Insulin Levels in Patients with Insulin-Treated Type 2 Diabetes: a Cross-Sectional Survey

Blood levels of true insulin and immunoreactive insulin in evaluating β-cell function with arginine stimulation test

The role of peripheral β-amyloid in insulin resistance, insulin secretion, and prediabetes: in vitro and population-based studies

[Insulin Regimes and Impact on Glycemic Control in Patients with Type 1 Diabetes].

Analysis of Insulin Doses of Chinese Type 2 Diabetic Patients with Intensive Insulin Treatment.

Analysis of the insulin dosage and impact factors of intensive insulin treatment of type 2 diabetic patients

[The Expression of Insulin Signal Transduction Molecules and Islet Alpha Cell Insulin Resistance].

Study on preparation and unique properties of a novel insulin analogue with N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at insulin B-chain

Effects of Timely Insulin Treatment on Protection of Beta Cells in a Rat Model of Type 2 Diabetes Mellitus.

An Optical Method to Evaluate Both Mass and Functional Competence of Pancreatic Α- and Β-Cells.

Clinical Research about the Unbalanced Statement of Angiogenic Growth Factors and Inhibitor with Retinopathy under Insulin Treatment in Type 2 Diabetics

Effect of Rat Proinsulin Gene Therapy by Intramuscular Injection on Blood Glucose in Streptozotocin-Induced Diabetic Rats

Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies